AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00299962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral-mediated Interferon-beta
Description: BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
Study NCT00299962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: Comparison of different doses and frequency of investigational agent
Study NCT03359291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
Study NCT03359291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
Study NCT02365220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No expectancy (control)
Description: No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
Study NCT02365220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective expectancy
Description: Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
Study NCT02365220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrospective expectancy
Description: Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
Study NCT02365220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective and retrospective expectancy
Description: Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
Study NCT03992664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDUCATION
Description: The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks.
Study NCT00654914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
Study NCT04298736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
Study NCT04298736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: guided low-calorie diet and physical activity.
Study NCT01329250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
Study NCT03349775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
Study NCT03349775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
Study NCT04026698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident and Family Engagement Intervention
Description: The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss a care related topic with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for up to 3 months.
Study NCT00337909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Study NCT00337909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational DVDs
Study NCT02718781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health talk
Description: Health talk on zero-time exercise.
Study NCT02718781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Health talk on zero-time exercise.
Study NCT02718781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular contact with community leaders
Description: Regular contact with community leaders to remind them do zero-time exercise.
Study NCT02718781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handgrip
Description: This is a home-based equipment
Study NCT01973374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Intervention
Study NCT02853448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Blood Drawing Apparatus
Study NCT04458662 — intervention group
Intervention type: PROCEDURE
Intervention: Interval running protocol / eccentric-based resistance exercise protocol
Study NCT02753322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: Balance and walking exercises with simultaneously engaging in attention demanding tasks
Study NCT02753322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-task training
Description: Balance and walking exercises and and attention demanding task performed separately
Study NCT02753322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limbs exercise
Description: Stretching and strengthening exercises
Study NCT00434421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerinated German cockroach allergenic extract
Description: Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters \[mL\], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose \[0.42 mL, 1:10 wt/vol\] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
Study NCT00434421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
Study NCT00829075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-FSH
Study NCT00829075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-hMG
Study NCT00829075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-FSH plus HP-hMG
Study NCT02877693 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic MRI Scan
Description: The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
Study NCT01414881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: mipomersen 200mg subcutaneously (SC) once weekly
Study NCT01414881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) once weekly
Study NCT02925702 — intervention group
Intervention type: DRUG
Intervention: Radium 223 55mBq/Kg every 4 weeks intravenously
Description: Radium-223 55kBq/kg infusion IV every 4 weeks
Study NCT01274715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Health Coaching
Description: Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
Study NCT03075813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Cluster
Description: Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
Study NCT02495844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0942
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
Study NCT02495844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB0942
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
Study NCT02495844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0942
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
Study NCT02495844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral use
Study NCT02921191 — intervention group
Intervention type: DRUG
Intervention: filgrastim, TBO-filgrastim or pegfilgrastim
Description: First cycle
Study NCT02097524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Study NCT02097524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Study NCT00820911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine (reduced exposure) / everolimus
Description: twice daily
Study NCT00820911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071 300 mg b.i.d. / everolimus
Description: twice daily
Study NCT00820911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071 200 mg b.i.d. / everolimus
Description: twice daily
Study NCT02091778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast gelling dressing
Study NCT01025960 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Inspection Colonoscopy
Description: The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
Study NCT01025960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Inspection Colonoscopy
Description: The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
Study NCT04638972 — intervention group
Intervention type: DEVICE
Intervention: working length determination techniques
Description: A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
Study NCT01417598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait and balance group training
Description: The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
Study NCT01417598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking (only osteoporosis group)
Description: To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
Study NCT04311697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil by intravenous infusion + standard of care
Description: Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
Study NCT04311697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Infusion + standard of care
Description: Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
Study NCT02285920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
Study NCT02285920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
Study NCT04594382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry-Opioid treatment
Description: At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes.
Study NCT04594382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry -standardized opioid treatment
Description: At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes.
Study NCT03420014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
Study NCT03420014 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: L19TNF plus doxorubicin
Description: 13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
Study NCT01871220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concave Transition Profile
Description: An Atlantis abutment is delivered with a concave transition profile.
Study NCT01871220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Divergent Transition Profile
Description: An Atlantis abutment is delivered with a linear transition profile
Study NCT03576599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid Injectable Product
Description: One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
Study NCT03576599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01688596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
Study NCT03450291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volatility task
Description: Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
Study NCT02645760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercise
Description: 7-weeks of core stabilization exercise
Study NCT02645760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: 7-weeks of conventional treatment include therapeutic ultrasound and hot pack
Study NCT02244320 — intervention group
Intervention type: DRUG
Intervention: Tamsulosin
Study NCT02781142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Description: The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
Study NCT01518881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKM-100201
Description: IV Infusion
Study NCT01518881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT01322503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus
Description: Norovirus challenge pool administered to each subject
Study NCT02075489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure treatment.
Description: Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for \~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for \~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
Study NCT02075489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reiki
Description: Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
Study NCT00853320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride tablet 15 mg
Description: Oxycodone hydrochloride tablet 15 mg, single dose fasting
Study NCT00853320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxicodone™ tablet 15 mg
Description: Roxicodone™ tablet 15 mg, single dose fasting
Study NCT00653614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)
Description: Single dose administration of E2 + DRSP as a tablet
Study NCT00653614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/DRSP (BAY 86-4891) dose 2 (80458739)
Description: Single dose administration of E2 + DRSP as a tablet
Study NCT00653614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/DRSP (BAY 86-4891) dose 3 (80458755)
Description: Single dose administration of E2 + DRSP as a tablet
Study NCT00653614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/DRSP (BAY 86-4891) dose 4 (80458720)
Description: Single dose administration of E2 + DRSP as a tablet